Evidence map›Paper›PMID 35337728›Full record

ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2022

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.

Yusuke Miyazato, Kei Yamamoto, Yuichiro Nakaya, Shinichiro Morioka, Junko S Takeuchi, Yuki Takamatsu, Kenji Maeda, Moto Kimura, Wataru Sugiura, Hiroaki Mitsuya and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yusuke MiyazatoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
Kei YamamotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan. Electronic address: kyamamoto@hosp.ncgm.go.jp.
Yuichiro NakayaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Division of Infectious Diseases, Shizuoka Cancer Center Hospital and Research Institute, Shizuoka, 411-8777, Japan.
Shinichiro MoriokaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
Junko S TakeuchiCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
Yuki TakamatsuDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
Kenji MaedaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
Moto KimuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
Wataru SugiuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
Masao YanoDepartment of Surgery, Minamimachida Hospital, Tokyo, 194-0004, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
National Center for Global Health and Medicine · JPSapporo Minami Hospital · JPShizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirmed to have neutralizing antibodies. This case suggests that monoclonal antibodies have therapeutic and prophylactic value in patients with humoral immunodeficiency.

Indexed as

Antineoplastic Agents, ImmunologicalCOVID-19 Drug TreatmentAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingFemaleHumansSARS-CoV-2Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntineoplastic Agents, ImmunologicalcasirivimabimdevimabAnti-CD20 monoclonal antibodyCasirivimab/imdevimabCOVID-19Neutralizing monoclonal antibodyRelapseRituximab

Identifiers

PMID35337728
PMCPMC8940576
OpenAlexW4220872777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.